Enorama Pharma Valuation
| ERMA Stock | SEK 3.76 0.13 3.34% |
At this time, the firm appears to be overvalued. Enorama Pharma AB shows a prevailing Real Value of kr3.53 per share. The current price of the firm is kr3.76. Our model computes the value of Enorama Pharma AB from reviewing the firm fundamentals such as Shares Owned By Insiders of 78.21 %, shares outstanding of 10.69 M, and Operating Margin of (3.11) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Enorama Pharma's price fluctuation is very risky at this time. Calculation of the real value of Enorama Pharma AB is based on 3 months time horizon. Increasing Enorama Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Enorama Pharma's intrinsic value may or may not be the same as its current market price of 3.76, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.76 | Real 3.53 | Hype 3.76 | Naive 3.77 |
The intrinsic value of Enorama Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enorama Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enorama Pharma AB helps investors to forecast how Enorama stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enorama Pharma more accurately as focusing exclusively on Enorama Pharma's fundamentals will not take into account other important factors: Enorama Pharma Total Value Analysis
Enorama Pharma AB is currently anticipated to have takeover price of 42.1 M with market capitalization of 89.44 M, debt of 1.7 M, and cash on hands of 2.01 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Enorama Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
42.1 M | 89.44 M | 1.7 M | 2.01 M |
Enorama Pharma Investor Information
About 78.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.92. Enorama Pharma AB had not issued any dividends in recent years. The entity had 1726:1687 split on the 29th of October 2018. Based on the key measurements obtained from Enorama Pharma's financial statements, Enorama Pharma AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Enorama Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enorama Pharma has an asset utilization ratio of 21.67 percent. This implies that the Company is making kr0.22 for each dollar of assets. An increasing asset utilization means that Enorama Pharma AB is more efficient with each dollar of assets it utilizes for everyday operations.Enorama Pharma Ownership Allocation
The market capitalization of Enorama Pharma AB is kr89.44 Million. Enorama Pharma AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 78.21 percent of Enorama Pharma AB outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Enorama Pharma Profitability Analysis
The company reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M.About Enorama Pharma Valuation
The stock valuation mechanism determines Enorama Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Enorama Pharma AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enorama Pharma. We calculate exposure to Enorama Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enorama Pharma's related companies.Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Enorama Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Enorama Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Enorama Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Enorama Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Enorama Pharma's revenue streams: Identify Enorama Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Enorama Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Enorama Pharma's growth potential: Evaluate Enorama Pharma's management, business model, and growth potential.
- Determine Enorama Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Enorama Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.